NASD · Healthcare · Biotechnology · USA
Outlook Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Outlook Therapeutics is a biopharmaceutical company that developed ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab approved in the European Union and United Kingdom for treating wet age-related macular degeneration. The company has launched the product in Germany and the UK, with an application pending for FDA approval in the United States.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Outlook Therapeutics Inc stock.
Not valued: We cannot value this company yet.
137 more in this industry show a wider margin of safety.
We do not publish a verdict on OTLK yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-16 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.